Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
Normann SteinerRadwan MassoudJohanna RichterTetiana PerekhrestenkoNico GagelmannChristian NiederwieserKristin RathjeIryna LastovytskaMathias SchäfersküpperSilke HeidenreichIna RudolphGaby ZeckDietlinde JansonChristine WolschkeFrancis Ayuketang AyukEvgeny KlyuchnikovNicolaus KrögerPublished in: European journal of haematology (2024)
Our study demonstrates that 8 Gy TBI in comparison to 12 Gy TBI results in low NRM but a high relapse rate with similar OS, LFS, and GRFS. In MRD+ high-risk ALL patients, allogeneic SCT with 12 Gy TBI leads to improved OS, LFS, GRFS, and a low relapse rate. Prospective studies comparing the different treatment regimens with larger MRD patient cohorts are needed to confirm this data.
Keyphrases
- traumatic brain injury
- acute lymphoblastic leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- low dose
- high dose
- allogeneic hematopoietic stem cell transplantation
- electronic health record
- machine learning
- case report
- big data
- artificial intelligence
- combination therapy
- data analysis
- hematopoietic stem cell